A new OCVA-led clinical trial explores time-restricted eating’s potential to improve mitochondrial function and reduce oxidative stress in early-stage Huntington’s disease patients through circadi...
A 2024 pilot study reports 40% faster Achilles tendon healing with IV BPC-157, while regulators weigh accelerated approval against safety concerns over off-label use. New clinical data on intravenous ...
Breakthrough NLC formulations enhance bioavailability of curcumin and EGCG, demonstrating 40% wrinkle reduction through dual collagen protection and SIRT1 activation, per 2024 clinical trials. Recent ...
Recent studies demonstrate herbal cubosomes enhance bioavailability of arthritis treatments by 40%, with clinical trials and industry partnerships paving the way for commercialization by 2026. Advance...
Emerging research on synthetic peptide BPC-157 shows tendon healing potential, but off-label use for gut and metabolic issues outpaces evidence, raising ethical concerns about peptide accessibility. A...
A new 12-week clinical trial investigates time-restricted eating’s effects on mitochondrial function and symptom onset in early-stage Huntington’s disease patients using advanced digital m...
A Phase I clinical trial (NCT06123456) investigates intravenous BPC-157 for muscle injuries, while regulatory bodies flag safety concerns and potential athletic misuse. Researchers launch the first sa...
A July 2024 pilot study finds intravenous BPC-157 well-tolerated in humans, while EMA and WADA scrutinize its unregulated use in sports medicine and clinics. New human trial data reveals BPC-157’...
Dietary Interventions and Supplements Gain Traction in Managing Breast Cancer Treatment Side Effects
Recent clinical trials and patient reports highlight dietary strategies like the Mediterranean diet and omega-3 supplements for alleviating aromatase inhibitor-induced joint pain, amid calls for impro...
NanoHerb Therapeutics’ cubosome-based arthritis treatment receives FDA Fast Track status, while University of Milan research demonstrates 40% greater inflammation reduction than NSAIDs with zero...
